Lisata Therapeutics (LSTA) Q3 2025 earnings summary

Executive summary

• Achieved key development milestones for certepetide, with positive preliminary results from ASCEND, ILSTA, Sendafox, and CENDIFOX trials, supporting its potential in anti-cancer regimens and broad applicability in solid tumors.

• Entered strategic alliances with GATC Health for AI-driven drug discovery and Catalent for global licensing of certepetide as a SMARTag ADC payload.

• Advanced multiple clinical programs and expanded the development pipeline, with ongoing efforts to secure additional licensing and partnership opportunities.

• Leadership team has extensive experience in biopharmaceutical development, aiming to address unmet medical needs in oncology.

• Cash runway extended into Q1 2027 with no debt, reflecting disciplined expense management.

Financial highlights

• Operating expenses for Q3 2025 were $4.4 million, down 17.3% year-over-year; R&D expenses decreased 22.9% to $2 million, and G&A expenses fell 12.1% to $2.5 million.

• Net loss for Q3 2025 was $4.2 million, compared to $4.9 million in Q3 2024; net loss for the nine months ended September 30, 2025 was $13.6 million, down from $15.4 million in the prior year period.

• Revenue for the nine months ended September 30, 2025 was $70,000, related to an upfront license fee.

• Cash and cash equivalents stood at $19 million as of September 30, 2025, with a projected runway into Q1 2027.

• Working capital was $17 million and stockholders' equity $17.4 million as of September 30, 2025.

Outlook and guidance

• Anticipates a data- and transaction-rich period in upcoming quarters, with several key clinical and business milestones expected.

• Final data from ASCEND and ILSTA trials expected in Q1 2026; additional Sendafox, BOLSTER, and CENDIFOX trial data anticipated in late 2025 and 2026.

• Phase III trial preparation underway, contingent on capital acquisition and partnership formation.

• Sufficient cash to fund operations for at least the next 12 months; additional financing likely needed by end of 2026 for long-term needs.

• Ongoing efforts to secure non-dilutive funding, partnerships, and potential equity or debt issuances.